QuidelOrtho's stock plummeted 24.69% during intraday trading on Thursday, reflecting significant selling pressure.
The sharp decline followed analyst actions, notably UBS adjusting its price target for QuidelOrtho down to $30 from $35 while maintaining a Neutral rating. This downward revision likely contributed to negative market sentiment toward the stock.
Other analyst updates included Citigroup raising its price target to $30 from $23, but this positive move was overshadowed by the UBS target cut during the trading session.